

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company or the Offeror nor is it a solicitation of any vote or approval in any jurisdiction. This joint announcement is not for release, publication or distribution in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.



Grand Full Development Limited
(創隆發展有限公司)
*(Incorporated in Hong Kong with
limited liability)*

**Bloomage BioTechnology
Corporation Limited**
華熙生物科技有限公司
*(Incorporated in the Cayman Islands
with limited liability)*
(Stock Code: 00963)

JOINT ANNOUNCEMENT
(1) PROPOSED PRIVATIZATION OF
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
BY GRAND FULL DEVELOPMENT LIMITED
BY WAY OF A SCHEME OF ARRANGEMENT
(UNDER SECTION 86 OF THE COMPANIES LAW)
AND
(2) PROPOSED WITHDRAWAL OF LISTING OF THE SHARES OF
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
FURTHER EXTENSION OF TIME FOR DESPATCH OF
THE SCHEME DOCUMENT

References are made to the joint announcement issued by the Offeror and the Company regarding the Proposal, the Scheme and the Option Offer dated 19 June 2017 (the “**Joint Announcement**”), the announcement of the Company dated 10 July 2017 in relation to the extension of time for the despatch of the Scheme Document to 8 September 2017 (the “**Extension Announcement**”) and the monthly update announcement of the Company dated 10 August 2017 (the “**Monthly Update**”).

Announcement”). Unless otherwise defined herein, terms used herein shall have the same meanings as defined in the Joint Announcement.

FURTHER EXTENSION OF THE TIME FOR DESPATCH OF THE SCHEME DOCUMENT

As set out in the Extension Announcement, as more time was required to accommodate the timetable of the Grand Court, an application for consent had been made to the Executive and the Executive had indicated that it was minded to grant consent for an extension to the time limit for despatching the Scheme Document to a date no later than 8 September 2017.

As set out in the Monthly Update Announcement, the Company and the Offeror were in the process of preparing the Scheme Document and had filed a petition, together with the draft Scheme Document, with the Grand Court for the convening hearing (the “**Convening Hearing**”). The Convening Hearing was duly held on 7 September 2017, and the Grand Court granted an order for, among other things, despatching the Scheme Document and the associated notices of meeting and proxy forms, and convening the Court Meeting.

As the Convening Hearing took place on 7 September 2017, the despatch date of the Scheme Document has to be postponed, so as to allow time for clearing the final version of the Scheme Document with the Executive and bulk-printing. As such, the despatch date of the Scheme Document has to be further postponed.

An application for consent for an extension to the time limit for despatching the Scheme Document has been made to the Executive and the Executive has granted consent for an extension to the time limit for despatching the Scheme Document to a date no later than 20 September 2017.

A detailed timetable for the Proposal, the Scheme and the Option Offer will be set out in the Scheme Document.

Warnings:

Shareholders, Optionholders and potential investors should be aware that the implementation of the Proposal, the Scheme and/or the Option Offer is subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal, the Scheme and the Option Offer may or may not be implemented and the Scheme may or may not become effective.

Shareholders, Optionholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their licensed securities dealers or registered institutions in securities, bank manager, solicitor or other professional advisers.

By Order of the Board of
Grand Full Development Limited
(創隆發展有限公司)
Zhao Yan
Director

By Order of the Board of
Bloomage BioTechnology Corporation Limited
(華熙生物科技有限公司)
Gong Anmin
Director

Hong Kong, 8 September 2017

As at the date of this joint announcement, the sole director of the Offeror is Ms. Zhao.

The sole director of the Offeror accepts full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Group) and confirms, having made all reasonable enquiries, that to the best of her knowledge, opinions expressed in this joint announcement (other than those expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, the Directors are:

Executive Directors:

Ms. Zhao Yan

Mr. Jin Xuekun

Mr. Gong Anmin

Ms. Wang Aihua

Non-executive Director:

Mr. Yau Wai Yan

Independent non-executive Directors:

Ms. Zhan Lili

Mr. Li Junhong

Mr. Xue Zhaofeng

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Offeror) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by the Offeror) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.